Dermokine as a novel biomarker for early-stage colorectal cancer
| Autor: | Tomoyuki Tagi, Issei Imoto, Fumie Kisumi-Hayashi, Toshiya Ochiai, Eigo Otsuji, Shojiro Kikuchi, Yoko Kinoshita-Ida, Toshio Imai, Yukihito Kokuba, Johji Inazawa, Takeshi Matsui, Sachi Hoshi, Koji Morimoto |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Pathology
medicine.medical_specialty Colorectal cancer Enzyme-Linked Immunosorbent Assay Sensitivity and Specificity Carcinoembryonic antigen Surgical oncology Submucosa Cell Line Tumor medicine Biomarkers Tumor Humans Neoplasm Staging Lamina propria biology business.industry Reverse Transcriptase Polymerase Chain Reaction Gastroenterology Cancer Proteins medicine.disease Gene Expression Regulation Neoplastic medicine.anatomical_structure Case-Control Studies biology.protein Immunohistochemistry Intercellular Signaling Peptides and Proteins Antibody business Colorectal Neoplasms |
| Zdroj: | Journal of gastroenterology. 45(12) |
| ISSN: | 1435-5922 |
| Popis: | Colorectal cancer is a common disease that is usually detected at an advanced stage, because early-stage cancer is mostly asymptomatic and appropriate serologic biomarkers have not been established. We have previously identified dermokine (DK) as a peptide secreted by keratinocytes and we found that DK-β/γ was expressed in colorectal tumors. Therefore, we focused on DK-β/γ as a new candidate diagnostic serum marker for early colorectal cancer. DK-β/γ expression in human colorectal cancer cell lines and tissues was assessed by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemistry. We established an experimental enzyme-linked immunosorbent assay (ELISA) to detect DK-β/γ in the serum of colorectal cancer patients, and we compared the sensitivities of common diagnostic markers, carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, and serum p53 antibody (S-p53). Immunohistochemical staining of colon tumor tissue with anti-DK monoclonal antibody (mAb) revealed that DK-β/γ was more commonly expressed in the early stages of colorectal cancer (Tis–T1; i.e., cancer in situ, intraepithelial or invasion of lamina propria [Tis]; tumor invades the submucosa [T1]) than in late-stage tumors (T2–T4; i.e., tumor invades the muscularis propria [T2]; tumor invades through the muscularis propria into the subserosa, or into the nonperitonealized pericolic or perirectal tissues [T3]; tumor directly invades other organs or structures and/or perforates visceral peritoneum [T4]). Serum DK-β/γ levels were determined in 130 patients with colorectal cancer and 25 healthy volunteers. Serum DK-β/γ was detected in 33.3% of patients with early colorectal cancer (Tis–T1), which was higher than the rates for S-p53 (24.2%), CEA (9.1%), and CA19-9 (0%). The serum DK-β/γ test was complementary to the other marker tests. Therefore, when the combined four-marker test (DK/CEA/CA19-9/S-p53) was carried out, the diagnostic sensitivity for Tis and T1 tumors reached 60.6%. Serum DK-β/γ is the most promising of the existing tumor biomarkers for the diagnosis of early-stage colorectal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink